Chemo-enzymatic synthesis of novel β-hydroxy-β-methylbutryric acid (HMB)-medium chain triacylglycerol (MCT) complexes

Cheong, Ling-Zhi,Widzisz, Katarzyna,Wang, Yingyao,Jensen, Henrik Helligso,Theil, Peter Kappel,Guo, Zheng,Xu, Xuebing

, p. 919 - 922 (2013)

β-Hydroxy-β-methylbutyrate (HMB) is reported to have ergogenic benefits such as reducing muscle wasting, promoting exercise performance and skeletal muscle hypertrophy. When used as a dietary feed, it has been found to improve colostral milk fat and the growth of piglets. Medium chain triacylglycerols (MCT) are a good energy source as they can be subjected to β-oxidation in the liver without being stored as fats. When used as animal feed, HMB-MCT complexes are reported to stimulate growth and produce leaner meat product. A high yield two-steps chemo-enzymatic pathway for synthesis of HMB-MCT complexes has been developed. Ethyl HMB ester was first synthesized using a chemical catalyst. Following that, it was transesterified with MCT by using a biocatalyst. Approximately 85 wt% of HMB-MCT complexes can be achieved using this two-step synthetic pathway. The reaction mechanism and some of the reaction parameters were also briefly elucidated.

Rathke,Lindert

, p. 3966 (1970)

Vuitel,Jacot-Guillarmod

, p. 608,609 (1972)

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

-

Paragraph 1692; 1703; 1704; 1705, (2019/06/07)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

N-(MONOCYCLIC ARYL),N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS

-

Paragraph 00627, (2014/06/11)

Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.